Literature DB >> 23682923

Drug absorption, distribution, metabolism and excretion considerations in critically ill adults.

Derek J Roberts1, Richard I Hall.   

Abstract

INTRODUCTION: All critically ill patients require medication to treat organ dysfunction. However, the pharmacokinetics of drugs used to treat these patients is complex due to frequent alterations in drug absorption, distribution, metabolism, and excretion (ADME). AREAS COVERED: This review examines pharmacokinetic aspects of drug administration for adult intensive care unit (ICU) patients. Specifically, the authors examine the ADME changes that occur and which should be considered by clinicians when delivering drug therapy to critically ill patients. EXPERT OPINION: Dosage pharmacokinetics determined from single-dose or limited-duration administration studies in healthy volunteers may not apply to critically ill patients. Organ dysfunction among these patients may be due to pre-existing disease or the effects of a systemic or locoregional inflammatory response precipitated by their illness. Alterations in pharmacokinetics observed among the critically ill include altered bioavailability after enteral administration, increased volume of distribution and blood-brain barrier permeability and changes in P-glycoprotein and cytochrome P450 enzyme function. However, the effect of these changes on clinically important outcomes remains uncertain and poorly studied. Future investigations should examine not only pharmacokinetic changes among the critically ill, but also whether recognition of these changes and alterations in drug therapy directed as a consequence of their observation alters patient outcomes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23682923     DOI: 10.1517/17425255.2013.799137

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  18 in total

1.  Susceptibility of Rickettsia rickettsii to Tigecycline in a Cell Culture Assay and Animal Model for Rocky Mountain Spotted Fever.

Authors:  Lucas S Blanton; Nicholas M Wilson; Bethany R Quade; David H Walker
Journal:  Am J Trop Med Hyg       Date:  2019-11       Impact factor: 2.345

Review 2.  Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials.

Authors:  Vincent Madelain; Thi Huyen Tram Nguyen; Anaelle Olivo; Xavier de Lamballerie; Jérémie Guedj; Anne-Marie Taburet; France Mentré
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

3.  Acetylsalicylic acid in critically ill patients: a cross-sectional and a randomized trial.

Authors:  Christian Schoergenhofer; Eva-Luise Hobl; Michael Schwameis; Georg Gelbenegger; Thomas Staudinger; Gottfried Heinz; Walter S Speidl; Christian Zauner; Birgit Reiter; Irene Lang; Bernd Jilma
Journal:  Eur J Clin Invest       Date:  2017-06-20       Impact factor: 4.686

Review 4.  Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development.

Authors:  T Burt; K Yoshida; G Lappin; L Vuong; C John; S N de Wildt; Y Sugiyama; M Rowland
Journal:  Clin Transl Sci       Date:  2016-03-30       Impact factor: 4.689

5.  Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.

Authors:  Thi Huyen Tram Nguyen; Jérémie Guedj; Xavier Anglaret; Cédric Laouénan; Vincent Madelain; Anne-Marie Taburet; Sylvain Baize; Daouda Sissoko; Boris Pastorino; Anne Rodallec; Géraldine Piorkowski; Sara Carazo; Mamoudou N Conde; Jean-Luc Gala; Joseph Akoi Bore; Caroline Carbonnelle; Frédéric Jacquot; Hervé Raoul; Denis Malvy; Xavier de Lamballerie; France Mentré
Journal:  PLoS Negl Trop Dis       Date:  2017-02-23

6.  A case report of intravenous posaconazole in hepatic and renal impairment patient with invasive Aspergillus terreus infection: safety and role of therapeutic drug monitoring.

Authors:  Pitchaya Dilokpattanamongkol; Panadda Panusitthikorn; Rasda Boonprasert; Methee Chayakulkeeree; Porpon Rotjanapan
Journal:  BMC Pharmacol Toxicol       Date:  2017-01-31       Impact factor: 2.483

7.  Prasugrel in critically ill patients.

Authors:  Christian Schoergenhofer; Eva-Luise Hobl; Thomas Staudinger; Walter S Speidl; Gottfried Heinz; Jolanta Siller-Matula; Christian Zauner; Birgit Reiter; Jacek Kubica; Bernd Jilma
Journal:  Thromb Haemost       Date:  2017-07-06       Impact factor: 5.249

8.  Intravenous zanamivir for influenza myocarditis and enteral malabsorption.

Authors:  Fritz-Patrick Jahns; Nawfel Ben-Hamouda; Matthias Kirsch; Aurélien Roumy; Lucas Liaudet
Journal:  Crit Care       Date:  2018-12-04       Impact factor: 9.097

Review 9.  Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling?

Authors:  Erin F Barreto; Andrew J Webb; Gwendolyn M Pais; Andrew D Rule; Paul J Jannetto; Marc H Scheetz
Journal:  Crit Care Explor       Date:  2021-06-11

10.  Tocilizumab administration in patients with SARS-CoV-2 infection: Subcutaneous injection vs intravenous infusion.

Authors:  Minoosh Shabani; Shervin Shokouhi; Omid Moradi; Ali Saffaei; Zahra Sahraei
Journal:  J Med Virol       Date:  2020-06-19       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.